Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort
Manon Girod(Université de Montpellier), O. Dereure(Beth Israel Deaconess Medical Center), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), J.-P. Arnault(Centre National de la Recherche Scientifique), S. Dalac(CHU Dijon Bourgogne), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Université Claude Bernard Lyon 1), E. Maubec(Délégation Paris 7), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k